Gang Qin PhD

Dr. Gang Qin has more than 16 years of R&D and managing experiences in biomedical research. He obtained his PhD degree at the European Neuroscience Institute, then he joined Max-Planck Institute of Biochemistry focusing on mechanistic characterization of protein degradation regulated cell proliferation. Thereafter, he moved back China and led one team at National Laboratory for Industrial Enzyme Engineering, CAS. At 2013 Dr. Qin founded GeneQuantum Healthcare (Suzhou ) Co. Ltd, currently he is the president. Dr. Qin has published series of high citation paper, he is also major inventor of multiple PCT patents. GeneQuantum’s innovative Ligase Dependent Conjugation (LDC) technology, combined with IP protected Automatic On-line Monitoring Conjugation System and Linker Screening& Optimization Facility, provide a holistic solution for the R&D of next generation ADCs. GeneQuantum are focusing on developing series of next generation anti-tumor ADCs with best-in-class or first-in-class potential fulfilling the unmet clinical need